Carisma TherapeuticsCARM
CARM
About: CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Employees: 68
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
3% more funds holding
Funds holding: 37 [Q3] → 38 (+1) [Q4]
0.82% less ownership
Funds ownership: 12.53% [Q3] → 11.71% (-0.82%) [Q4]
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
60% less capital invested
Capital invested by funds: $5.11M [Q3] → $2.05M (-$3.06M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
2,887%
upside
Avg. target
$12
2,887%
upside
High target
$12
2,887%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 26% 1-year accuracy 72 / 279 met price target | 2,887%upside $12 | Buy Maintained | 17 Jan 2025 |
Financial journalist opinion
Neutral
PRNewsWire
3 weeks ago
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
PHILADELPHIA , Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.
Neutral
PRNewsWire
1 month ago
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
PHILADELPHIA , Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
Neutral
PRNewsWire
3 months ago
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA , Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies.
Neutral
PRNewsWire
3 months ago
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA , Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5 th at 9:35 am ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
Neutral
PRNewsWire
3 months ago
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity PHILADELPHIA , Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. These results underscore the pre-clinical efficacy of Carisma's engineered macrophages in multiple liver fibrosis models and offer a novel, off-the-shelf potential treatment option for patients with fibrotic liver disease including advanced metabolic dysfunction-associated steatohepatitis (MASH).
Neutral
PRNewsWire
4 months ago
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully create CAR-M directly in vivo, reprogramming endogenous myeloid cells to target and destroy Glypican-3 ("GPC3"), expressing cancer cells.
Neutral
PRNewsWire
4 months ago
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting New preclinical efficacy data in liver fibrosis to be presented on November 17 at AASLD - The Liver Meeting ® 2024 Cash and cash equivalents of $26.9 million expected to fund the Company into the third quarter of 2025 PHILADELPHIA , Nov. 7, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2024, and highlighted recent business updates. "Our recent progress across clinical and preclinical programs demonstrates our commitment to pioneering therapies that address significant unmet medical needs," said Steven Kelly, President and CEO of Carisma Therapeutics.
Neutral
PRNewsWire
4 months ago
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a poster session at the Society for Immunotherapy of Cancer ("SITC") Annual Meeting in Houston, Texas, on November 8, 2024.
Neutral
PRNewsWire
4 months ago
Carisma Therapeutics Announces Changes to its Board of Directors
Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA , Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments.
Neutral
PRNewsWire
5 months ago
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
PHILADELPHIA , Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024. Details on the poster presentations at SITC 2024 are below: Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma Publication Number: 329 Session Date & Time: Friday, Nov. 8, 2024 Location: Exhibit Halls A B George R.
Charts implemented using Lightweight Charts™